Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment. These solutions are designed to support purification, separation, monitoring and efficient handling of biological materials while helping biopharmaceutical producers improve manufacturing processes.

Founded in 1981, Repligen is headquartered in Waltham, Massachusetts, and serves biopharmaceutical and life sciences customers internationally. The company has expanded its offerings through internal development and acquisitions, including businesses focused on filtration, chromatography, single-use systems and process analytics. Tony J. Hunt has served as Repligen’s president and chief executive officer since 2015.

Key Stats

• Today's Range: $175.39 to $181.07
• 50-Day Range: $158.59 to $194.57
• 52-Week Range: $100.99 to $198.87
• Volume: 1.22 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: $10.06 billion
• P/E Ratio: 244.11
• Dividend Yield: N/A
• Price Target: $173.21
• Consensus Rating: Moderate Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 44% of companies evaluated by MarketBeat, and ranked 639th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 12 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Repligen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Repligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 26.70%

Earnings Growth

Earnings for Repligen are expected to grow by 26.70% in the coming year, from $2.06 to $2.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is 244.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is 244.38, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.40.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 3.15. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.52% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 6.61.

Change versus previous month

Short interest in Repligen has recently increased by 12.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.04

News Sentiment

Repligen has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Repligen this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 449-9560
• Fax: 781-250-0115
• Employees: 2,000
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $173.21
• High Price Target: $225.00
• Low Price Target: $142.00
• Potential Upside/Downside: -2.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.73
• Trailing P/E Ratio: 244.11
• Forward P/E Ratio: 86.50
• P/E Growth: 3.15
• Net Income: $48.89 million
• Net Margins: 5.29%
• Pretax Margin: 6.64%
• Return on Equity: 5.30%
• Return on Assets: 3.79%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 9.05
• Quick Ratio: 7.64

Sales & Book Value

• Annual Sales: $738.26 million
• Price / Sales: 13.62
• Cash Flow: $3.53 per share
• Price / Cash Flow: 50.49
• Book Value: $37.42 per share
• Price / Book: 4.76

Miscellaneous

• Outstanding Shares: 56,440,000
• Free Float: 56,097,000
• Market Cap: $10.06 billion
• Optionable: Optionable
• Beta: 1.08